natgillin/translations-raw huggingface dataset:
* measured by SRH assay seroprotection: SRH area ≥25 mm2, seroconversion: SRH area ≥25 mm2 for subjects with a baseline SRH area ≤4 mm2 or a minimum 50% increase in SRH area for subjects with >4 mm2.
za ispitanike s početnom vrijednošću SRH površine ≤4 mm2 ili minimalni porast od 50% SRH površine za ispitanike s >4 mm2. ** omjeri srednje geometrijske vrijednosti SRH
They should not be used during pregnancy and breastfeeding.
Ne smiju se koristiti tijekom trudnoće i dojenja.
This means that there are bibliographic data providing scientific evidence of their effectiveness and safety when used in this way, covering a period of at least 10 years in the EU.
To znači da postoje bibliografski podaci koji pružaju znanstvene dokaze o njihovoj djelotvornosti i sigurnosti kada se koriste na opisani način i obuhvaćaju razdoblje od najmanje 10 godina u EU.
Castor oil medicines should only be used in adults, and should not be taken for longer than one week without medical supervision.
Lijekovi od ricinusovog ulja smiju se primjenjivati samo u odraslih osoba i ne smiju se koristiti dulje od jednog tjedna bez medicinskog nadzora.
This means that the oil is extracted from the seeds by crushing and pressing them without heating.
To znači da se ulje ekstrahira iz sjemenki drobljenjem i prešanjem bez zagrijavanja.
5 April 2016 EMA/108531/2016
EMA/108531/2016
Castor oil EMA/108531/2016
Ricinusovo ulje EMA/108531/2016
These include nausea, vomiting abdominal (belly) pain and severe diarrhoea.
One uključuju mučninu, povraćanje, abdominalne bolove (bol u trbuhu) i težak proljev.
This increases the water content of stools, making them softer and easier to pass.
Time se povećava sadržaj vode u stolici, čime ona postaje mekša i lakše prolazi kroz crijeva.
Castor oil medicines should not be taken in case of obstruction or narrowing of the gut, atony (loss of normal movement in the gut muscle), appendicitis (inflammation of the appendix, a small organ connected to the bowel), inflammatory diseases of the colon (the lower part of the bowel), unexplained abdominal pain and severe dehydration.
Lijekovi koji sadrže ricinusovo ulje ne smiju se uzimati u slučaju opstrukcije ili suženja crijeva, atonije (gubitka normalnih kretnji mišića crijeva), apendicitisa (upala crvuljka („slijepog crijeva”), malog organa spojenog s crijevima), upale debelog crijeva (donjeg dijela crijeva), neobjašnjenih abdominalnih bolova i teške dehidracije.
Any applications for the licensing of medicines containing castor oil have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC.
Svi zahtjevi za odobrenje lijekova koji sadrže ricinusovo ulje moraju se podnijeti nacionalnim tijelima nadležnima za lijekove, koja ocjenjuju zahtjev za biljni lijek i uzimaju u obzir znanstvene zaključke HMPC-a.
What is castor oil?
Što je ricinusovo ulje?
Further information on the HMPC assessment of castor oil medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Dodatne informacije o HMPC-ovoj ocjeni lijekova koji sadrže ricinusovo ulje, uključujući pojedinosti zaključaka Povjerenstva, mogu se pronaći pod karticom „All documents” na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Herbal medicines for human use.
How does castor oil work as a medicine?
Kako ricinusovo ulje djeluje kao lijek?
When ingested, castor oil is broken down into ricinoleic acid which works by reducing absorption of fluid and salts in the small intestine (the upper part of the bowel).
Nakon gutanja, ricinusovo ulje razgrađuje se na ricinoleatnu kiselinu, koja djeluje tako što smanjuje apsorpciju tekućina i soli u tankom crijevu (gornjem dijelu crijeva).
Castor oil
Ricinusovo ulje
This summary is not intended to provide practical advice on how to use medicines containing castor oil.
Svrha ovog sažetka nije davati praktične savjete o načinu primjene lijekova koji sadrže ricinusovo ulje.
Further information on the risks associated with castor oil medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Više o rizicima povezanima s lijekovima koji sadrže ricinusovo ulje, uključujući odgovarajuće mjere opreza za njihovu sigurnu primjenu, možete pronaći u monografiji pod karticom „All documents” na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Herbal medicines for human use.
Herbal medicines containing these castor oil preparations are usually available in solid or liquid forms to be taken by mouth.
Biljni lijekovi koji sadrže te pripravke ricinusovog ulja najčešće su dostupni u krutom ili tekućem obliku i uzimaju se kroz usta.
In one of the studies the effects of castor oil capsules were similar to those of senna capsules (another herbal preparation commonly used to treat constipation).
U jednom od ispitivanja učinak kapsula s ricinusovim uljem bio je sličan učinku kapsula sa senom (drugi biljni pripravak koji se često primjenjuje u liječenju zatvora).
Castor oil preparations may also be found in combination with other herbal substances in some herbal medicines.
Pripravci ricinusovog ulja mogu postojati također i u kombinaciji s drugim biljnim tvarima u nekim biljnim lijekovima.
Information on the use and licensing of castor oil medicines in EU Member States should be obtained from the relevant national authorities.
Informacije o primjeni i davanju odobrenja za lijekove koji sadrže ricinusovo ulje u državama članicama EU-a mogu se dobiti od nadležnih nacionalnih tijela.
The HMPC conclusions on the use of these castor oil medicines as laxatives are based on their ‘wellestablished use'.
Zaključci HMPC-a o primjeni ovih lijekova koji sadrže ricinusovo ulje kao laksativa temelje se na njihovoj „provjerenoj medicinskoj uporabi”.
In its assessment, the HMPC considered two clinical studies which showed a laxative effect for castor oil medicines in constipated patients.
Prilikom svoje ocjene HMPC je razmotrio dva klinička ispitivanja koja su pokazala laksativni učinak lijekova s ricinusovim uljem u bolesnika sa zatvorom.
The HMPC concluded that these castor oil preparations can be used for short term as laxatives for occasional constipation.
HMPC je zaključio da se ovi pripravci ricinusovog ulja mogu kratkotrajno koristiti kao laksativi kod povremenog zatvora.
This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of castor oil.
Ovaj dokument predstavlja sažetak znanstvenih zaključaka Povjerenstva za biljne lijekove (HMPC) u pogledu medicinske primjene ricinusovog ulja.
In addition, castor oil stimulates movement in the intestines which will help to pass the stools.
Osim toga, ricinusovo ulje stimulira crijevne kretnje, što pomaže pražnjenju stolice.
Detailed instructions on how to take castor oil medicines and who can use them can be found in the package leaflet that comes with the medicine.
Detaljne upute o načinu uzimanja lijekova koji sadrže ricinusovo ulje i o tome tko ih smije uzimati navedene su u uputi o lijeku koja je priložena uz lijek.
Other information about castor oil medicines
Ostale informacije o lijekovima koji sadrže ricinusovo ulje
What are the risks associated with castor oil medicines?
Koji su rizici povezani s lijekovima koji sadrže ricinusovo ulje?
For more information about treatment with castor oil medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist.
Za više informacija o liječenju lijekovima koji sadrže ricinusovo ulje pročitajte uputu o lijeku priloženu uz lijek, odnosno obratite se svom liječniku ili ljekarniku.
For practical information about using castor oil medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist.
Za praktične informacije o primjeni lijekova koji sadrže ricinusovo ulje bolesnici trebaju pročitati uputu o lijeku priloženu uz lijek, odnosno obratiti se svom liječniku ili ljekarniku.
Side effects have been reported with castor oil.
Prijavljene su nuspojave kod primjene ricinusovog ulja.
How are castor oil medicines approved in the EU?
Kako se u EU-u odobravaju lijekovi koji sadrže ricinusovo ulje?
Castor oil is the common name for the oil obtained from the seeds of the plant Ricinus communis L. The HMPC conclusions only cover castor oil preparations which are obtained by ‘cold expression' of the seeds.
Ricinusovo ulje je uobičajen naziv za ulje koje je dobiveno iz sjemenki biljke Ricinus communis L.
Member States when evaluating applications for the licensing of herbal medicines containing castor oil.
Države članice EU-a uzimaju u obzir zaključke HMPC-a prilikom ocjene zahtjeva za davanje odobrenja za biljne lijekove koji sadrže ricinusovo ulje.
What evidence supports the use of castor oil medicines?
Kojim se dokazima potkrjepljuje primjena lijekova koji sadrže ricinusovo ulje?
<Similarity>
<Sličnost>
<Derogation>
<Odstupanje>
Conditional marketing authorisation
Uvjetno odobrenje za stavljanje lijeka u promet
[For Art 14(11)] <The CHMP reviewed the data submitted by the Marketing Authorisation Holder, taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004, and considers that the new therapeutic indication brings significant clinical benefit in comparison with existing therapies as further explained in the European Public Assessment Report.
[For Art 14(11)] <CHMP je pregledao podatke koje je dostavio nositelj odobrenja, uzevši u obzir odredbe čl. 14(11) Uredbe (EZ) br. 726/2004, te smatra da nova terapijska indikacija donosi značajnu kliničku korist u usporedbi s postojećim terapijama, što je dodatno pojašnjeno u Europskom javnom izvješću o ocjeni lijeka.
CONCLUSIONS ON THE GRANTING OF THE CONDITIONAL MARKETING AUTHORISATION AND <SIMILARITY AND DEROGATION> <AND> < THE REQUEST FOR ONE-YEAR <MARKETING PROTECTION> <DATA EXCLUSIVITY>> PRESENTED BY THE EUROPEAN MEDICINES AGENCY
ZAKLJUČCI EUROPSKE AGENCIJE ZA LIJEKOVE O DAVANJU UVJETNOG ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET TE <SLIČNOSTI I ODSTUPANJU> <I> < ZAHTJEVU ZA JEDNOGODIŠNJU <ZAŠTITU STAVLJANJA LIJEKA U PROMET> <ZAŠTITU PODATAKA O LIJEKU>>
<one-year <marketing protection><data exclusivity>>
<Jednogodišnja <zaštita stavljanja lijeka u promet> <zaštita podataka o lijeku>>
[Art 10(5)] <The CHMP reviewed the data submitted by the Marketing Authorisation Holder, taking into account the provisions of Article 10(5) of Directive 2001/83/EC, and considers that <the <pre-clinical tests> <and> <clinical studies> carried out in relation to the new indication were significant as further explained in the European Public Assessment Report.
[Art 10(5)] <CHMP je pregledao podatke koje je dostavio nositelj odobrenja, uzevši u obzir odredbe čl. 10(5) Direktive 2001/83/EZ, te smatra da su <pretklinička ispitivanja> <i> <klinička ispitivanja> provedena u vezi s novom indikacijom bila značajna, što je dodatno pojašnjeno u Europskom javnom izvješću o ocjeni lijeka.
The CHMP having considered the application is of the opinion that the risk-benefit balance is favourable to recommend the granting of the conditional marketing authorisation as further explained in the European Public Assessment Report.
Nakon razmatranja zahtjeva, mišljenje je CHMP-a da je omjer rizika i koristi povoljan te se može preporučiti davanje uvjetnog odobrenja za stavljanje lijeka u promet, što je dodatno pojašnjeno u Europskom javnom izvješću o ocjeni lijeka.
<the holder of the marketing authorisation for <authorised orphan medicinal product> is unable to supply sufficient quantities of the medicinal product> <and>
<nositelj odobrenja za <odobreni lijek za rijetke i teške bolesti> ne može isporučiti dovoljne količine lijeka> <i>
<the holder of the marketing authorisation for <authorised orphan medicinal product> has given his consent to the applicant.>
<nositelj odobrenja za <odobreni lijek za rijetke i teške bolesti> dao je svoju suglasnost podnositelju zahtjeva.>
<The CHMP is of the opinion that pursuant to Article 8 of Regulation (EC) No. 141/2000 and <Article 3 of Commission Regulation (EC) No 847/2000> [only for the superiority derogation] the following derogation
 laid down in Article 8.3 of the same Regulation apply(ies) as further explained in European Public Assessment Report :
3 Uredbe Komisije (EZ) br. 847/2000> [only for the superiority derogation], primjenjuje(u) sljedeće(a) odstupanje(a) navedeno(a) u čl. 8.3 iste Uredbe, što je dodatno pojašnjeno u Europskom javnom izvješću o ocjeni lijeka:
<the applicant could establish in the application that the medicinal product, although similar to <authorised orphan medicinal product>, is safer, more effective or otherwise clinically superior (as defined in Article 3 of Commission Regulation (EC) No. 847/2000) for the same therapeutic indication> <and>
<podnositelj zahtjeva može utvrditi u zahtjevu da je lijek, iako sličan <odobrenom lijeku za rijetke i teške bolesti>, sigurniji, učinkovitiji ili na neki drugi način klinički superiorniji (prema definicijama u čl.
<The CHMP is of the opinion that <name of product> is similar to authorised orphan medicinal products within the meaning of Article 3 of Commission Regulation (EC) No. 847/2000 as further explained in the European Public Assessment Report.
<Mišljenje je CHMP-a da je <naziv lijeka> sličan odobrenim lijekovima za rijetke i teške bolesti (“orphan” lijek) sukladno čl.
Str. Aleea Eroilor nr. 28 Vişeu de Sus
Aleea Eroilor nr. 28 Vişeu de Sus
Rua Prof. Sousa da Câmara,
Sousa da Câmara,
Austria ratiopharm Arzneimittel VertriebsGmbH Albert-Schweitzer-Gasse 3 1140 Vienna
Austrija ratiopharm Arzneimittel VertriebsGmbH Albert-Schweitzer-Gasse 3 1140 Vienna
Belgium Teva Pharma Belgium N.V. Laarstraat 16
Teva Pharma Belgium N.V. Laarstraat 16
Orifarm Generics A/S PO 69, Energivej 15 DK-5260 Odense S Denmark
Orifarm Generics A/S PO 69, Energivej 15 DK-5260 Odense
2909 LD Capelle aan den IJssel The Netherlands
2909 LD Capelle aan den IJssel The Netherlands diklofenaknatrij mizoprostol
United Kingdom Crescent Pharma Limited Unit 3&4
Crescent Pharma Limited Unit 3&4
United Kingdom Aptil Pharma limited 9th Floor
Aptil Pharma limited 9th Floor
Pfizer AS Lilleakerveien 2B 1324 Lysaker Norway
Pfizer AS Lilleakerveien 2B 1324 Lysaker Norway diklofenaknatrij mizoprostol
Capsule
kapsula
Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the Member States
Dodatak I Popis imena, farmaceutskih oblika, jačina lijekova, puteva primjene,
Finland ratiopharm Oy P.O.Box 67
Finska ratiopharm Oy P.O.Box 67
United Kingdom Galen Limited Seagoe Industrial Estate Craigavon
Galen Limited Seagoe Industrial Estate Craigavon
United Kingdom Chelonia Healthcare Limited Boumpoulinas 11
Chelonia Healthcare Limited Boumpoulinas 11
N. Psychiko, 15451 Greece
Psychiko, 15451 Greece
97-107 Uxbridge Road London W5 5TL
97-107 Uxbridge Road London W5 5TL United Kingdom diklofenakkalij
Scandinavian Regulatory Services, AB Svardvagen 3B Stockholm SE-182 33 Sweden
Scandinavian Regulatory Services, AB Svardvagen 3B Stockholm SE-182 33 Sweden diklofenakkalij
Luxembourg Continental Pharma Rijksweg, 12
Luksemburg Continental Pharma Rijksweg, 12
pot k sejmišču 35 1231 Ljubljana Črnuče Slovenia
Pliva Ljubljana d.o.o. pot k sejmišču 35 1231 Ljubljana Črnuče Slovenia
United Kingdom Chatfield Pharmaceuticals Limited
Chatfield Pharmaceuticals Limited
Pinewood Laboratories Ltd (T/A Pinewood Heathcare) Ballymacarbry Clonmel, Co. Tipperary Ireland
Pinewood Laboratories Ltd (T/A Pinewood Heathcare) Ballymacarbry Clonmel, Co.
Luxembourg Hexal AG Industriestraße 25
Luksemburg Hexal AG Industriestraße 25
Diclofenac potassium CATAFLAM ORAL DROPS 1.5%
CATAFLAM ORAL DROPS 1.5%
A/S “Olainfarm” Rupnicu iela 5 Olaine, LV - 2114 Latvia
A/S “Olainfarm” Rupnicu iela 5 Olaine, LV - 2114 Latvia diklofenakkalij
Pfizer Enterprises SARL Round-Point du Kirchberg 51, Avenue J.F.Kennedy L-1855 Luxembourg Luxembourg
Pfizer Enterprises SARL Round-Point du Kirchberg 51, Avenue J.F.Kennedy L-1855 Luxembourg Luxembourg diklofenak mizoprostol
Luxembourg Daiichi Sankyo Belgium SA Rue Fond Jean Pâques 5
Luksemburg Daiichi Sankyo Belgium SA Rue Fond Jean Pâques 5
de Europa, 20 B Parque Empresarial La Moraleja 28108 Alcobendas (Madrid) Spain
Avda. de Europa, 20 B Parque Empresarial La Moraleja 28108 Alcobendas (Madrid) Spain diklofenaknatrij mizoprostol
Box 51706 Lemesos Cyprus
P.O. Box 51706 Lemesos Cyprus
182 12 Danderyd Sweden
182 12 Danderyd Sweden diklofenakkalij
United Kingdom Co-Pharma Limited Unit 4, Metro Centre Tolpits Lane, Watford Hertfordshire WD18 9SS United Kingdom
Co-Pharma Limited Unit 4, Metro Centre Tolpits Lane, Watford Hertfordshire WD18 9SS United Kingdom
Novartis Finland OY Metsänneidonkuja 10 FIN-02130 Espoo Finland
Metsänneidonkuja 10 FIN-02130 Espoo Finland
Remedica ltd Aharnon str. P.O.
Remedica ltd Aharnon str.
110 B 20097 Hamburg Germany
Spaldingstr. 110 B 20097 Hamburg Germany
SC ANTIBIOTICE SA Str. Valea Lupului nr. 1 6600-Iaşi
Valea Lupului nr. 1 6600-Iaşi
Not applicable for bolus intravenous injection
Nije primjenjivo za bolusnu injekciju u venu
Vetenskapsvägen 10 191 90 Sollentuna Sweden
Vetenskapsvägen 10 191 90 Sollentuna Sweden diklofenaknatrij mizoprostol
Actavis A/S Ornegardsvej 16 2820 Gentofte Denmark
Actavis A/S Ornegardsvej 16 2820 Gentofte Denmark diklofenakkalij
United Kingdom Mercury Pharma International Limited
Mercury Pharma International Limited
United Kingdom Sandoz Limited Frimley Business Park Frimley
Sandoz Limited Frimley Business Park Frimley
BIOTECH Pharmaceutical Ltd Larissis 10
D.A.S.T. BIOTECH Pharmaceutical Ltd Larissis 10
Actavis EAD 29 Atanas Dukov Str. Sofia 1407
Actavis EAD 29 Atanas Dukov Str.
Lagoas Park, Edifício 10 2740-271 Porto Salvo Portugal
Lagoas Park, Edifício 10 2740-271 Porto Salvo Portugal diklofenak mizoprostol
Granules for oral suspension
granule za oralnu suspenziju
Chile, 8-2ª planta.
GERMED FARMACEUTICA, S.L. Chile, 8-2ª planta.
Pfizer ApS Lautrupvang 8 DK-2750 Ballerup Denmark
Pfizer ApS Lautrupvang 8 DK-2750 Ballerup Denmark diklofenaknatrij mizoprostol
United Kingdom Ennogen Pharma Limited Unit G4, Riverside Way Dartford, DA1 5BS
Ennogen Pharma Limited Unit G4, Riverside Way Dartford, DA1 5BS United Kingdom
Morningside Healthcare Limited 115 Narborough Road Leicester, LE3 0PA United Kingdom
Morningside Healthcare Limited 115 Narborough Road Leicester, LE3 0PA United Kingdom diklofenaknatrij mizoprostol
United Kingdom Chiesi Limited Cheadle Royal Business Park Highfield, Cheadle Cheshire SK8 3GY United Kingdom
Cheadle Royal Business Park Highfield, Cheadle Cheshire SK8 3GY
Via Cassia Nord 351 Darvia - 53014 Siena Italy
Industria Farmaceutica Galenica Senese S.r.l. Via Cassia Nord 351 Darvia - 53014 Siena Italy
Miles Gray Road Basildon, Essex SS14 3RF United Kingdom
Waymade Plc Regency House Miles Gray Road Basildon, Essex SS14 3RF United Kingdom
TRATUL 120 mg 120mg
TRATUL 120 mg 120 mg čepić rektalno
Diclofenac potassium VOLTATABS 12,5 MG(EX:ZYMAMED)
VOLTATABS 12,5 MG(EX:ZYMAMED)
G. KORONIS Dilou 9, Peristeri Attikis, 12134
PHARMACEUTICAL INDUSTRY PROEL EPAM. G. KORONIS Dilou 9, Peristeri Attikis, 12134
Via Sette Santi 3, Firenze 50131- Italy
Menarini Industrie Farmaceutiche Riunite S.r.l. Via Sette Santi 3, Firenze 50131- Italy
2333 CN Leiden The Netherlands
2333 CR Leiden The Netherlands
Luxembourg Mylan bvba Rozendal Businesspark Terhulpsesteenweg 6A B-1560 Hoeilaart Belgium
Luksemburg Mylan bvba Rozendal Businesspark Terhulpsesteenweg 6A B-1560 Hoeilaart Belgium
Park View, Riverside Way Watchmoor Park, Camberley Surrey GU15 3YL United Kingdom
Park View, Riverside Way Watchmoor Park, Camberley Surrey GU15 3YL United Kingdom diklofenakkalij
FLECTOR RAPID 50 mg granulátum
FLECTOR RAPID 50 mg granulátum granule
Largo Donegani 4/a Novara - 28100 Italy
Proge Farm S.r.l. Largo Donegani 4/a Novara - 28100 Italy
Leskoškova cesta 9D 1000 Ljubljana Slovenia
Medias International d.o.o. Leskoškova cesta 9D 1000 Ljubljana Slovenia
Luxembourg Novartis Consumer Health S.A. Medialaan, 40
Luksemburg Novartis Consumer Health S.A. Medialaan, 40
Diclofenac sodium DICLOFENACO ALDO-UNION comprimidos EFG
DICLOFENACO ALDO-UNION comprimidos EFG
NOVARTIS SANTE FAMILIALE 14, boulevard Richelieu 92500 Rueil-Malmaison France
NOVARTIS SANTE FAMILIALE 14, boulevard Richelieu 92500 Rueil-Malmaison France diklofenakkalij
Pharma GmbH Schlossplatz 1
G.L. Pharma GmbH Schlossplatz 1
Rowex Ltd Bantry, Co. Cork Ireland
Rowex Ltd Bantry, Co.
S.C. AC HELCOR PHARMA SRL Str. Victor Babeş nr. 50 Baia-Mare
S.C. AC HELCOR PHARMA SRL Str.
Luxembourg Socobom S.A Avenue Louise 149 b24 B-1050 Bruxelles Belgium
Luksemburg Socobom S.A Avenue Louise 149 b24
United Kingdom Therabel pharma UK Limited Compass House, vision Park Chivers, Histon
Therabel pharma UK Limited Compass House, vision Park Chivers, Histon Cambridge CB24 9AD United Kingdom
Via Ragazzi del 99 5, Bologna - 40133 Italy
Alpha Biotech S.r.l. Via Ragazzi del 99 5, Bologna - 40133 Italy
Prolonged-release tablet hameln pharma plus gmbh Langes Feld 13
Njemačka hameln pharma plus gmbh Langes Feld 13
Pfizer Hellas A.E. Messoghion Ave. 243 Neo Psychiko 15451 Greece
Messoghion Ave. 243 Neo Psychiko 15451 Greece diklofenaknatrij mizoprostol
Sopharma Pharmaceuticals 5 Lachezar Stanchev Str. Sofia 1220
Sopharma Pharmaceuticals 5 Lachezar Stanchev Str.
United Kingdom Teva UK Limited Brampton Road
Teva UK Limited Brampton Road Hampden Park Eastbourne
Diclofenac potassium Doble action pain relief
Doble action pain relief
Pfizer Europe MA EEIG Ramsgate Road Kent, Sandwich CT13 9NJ United Kingdom
Pfizer Europe MA EEIG Ramsgate Road Kent, Sandwich CT13 9NJ United Kingdom diklofenak mizoprostol
PANNONPHARMA Gyógyszergyártó Kft. PannonPharma út 1.
PannonPharma út 1.
Diclofenac sodium Diclo 100 retard - 1 A Pharma
Diclo 100 retard - 1 A Pharma
89340 Leipheim Germany
89340 Leipheim Germany diklofenakkalij
London SW5 9JL
Kramer Mews London SW5 9JL United Kingdom
Flector EP Rapid 50 mg
Flector EP Rapid 50 mg granule
Kent CT13 9NJ United Kingdom
Kent CT13 9NJ United Kingdom diklofenaknatrij mizoprostol
Astellas Pharma Co. Ltd 5 Waterside
Ltd 5 Waterside
Via Isonzo 71 Latina 04100 Italy
Pfizer Italia S.r.l. Via Isonzo 71 Latina 04100 Italy diklofenaknatrij mizoprostol
Controlled release capsule
kapsula s kontroliranim oslobađanjem
Capsules 100mg
100 mg kapsula
Laboratoires Genevrier 280, rue de Goa Les Trois Moulins - Parc de Sophia Antipolis 06600 Antibes France
Laboratoires Genevrier 280, rue de Goa Les Trois Moulins - Parc de Sophia Antipolis 06600 Antibes France diklofenakepolamin FLECTOR 50 mg, granulés pour solution buvable en sachet-dose granule za oralnu otopinu
Diclofenac sodium Diclo-B G.L.
Diclo-B G.L.
Diclofenacum natricum Olfen Depocaps 100 mg prolongedrelease capsules, hard
Olfen Depocaps 100 mg prolongedrelease capsules, hard
Diclofenac sodium Diclofenac SFRotexmedica
Diclofenac SFRotexmedica
Diclofenac sodium Olfen-100 SR Depocaps
Olfen-100 SR Depocaps
Diclofenac sodium Diclofenac 100 Heumann Supp.
Diclofenac 100 Heumann Supp.
Diclofenac potassium Voltarol Pain-Eze Tablets
Voltarol Pain-Eze Tablets
Pharmacia GmbH Linkstrasse 10 10785 Berlin Germany
Pharmacia GmbH Linkstrasse 10 10785 Berlin Germany diklofenaknatrij mizoprostol
Diclofenac sodium Diclofenac AL 50 Supp.
Diclofenac AL 50 Supp.
United Kingdom RI Pharma Limited First floor,6 St John's Court Upper Fforest Way
RI Pharma Limited First floor,6 St John's Court Upper Fforest Way Swansea Enterprise Park Swansea SA6 8QQ United Kingdom
Rectal use betapharm Arzneimittel GmbH Kobelweg 95
Njemačka betapharm Arzneimittel GmbH Kobelweg 95
Prolonged-release tablet sigapharm GmbH Temmlerstr.
Njemačka sigapharm GmbH Temmlerstr.
Via Enrico Fermi 1 Alanno (PE) 65020 Italy
Alfa Wassermann S.p.A. Via Enrico Fermi 1 Alanno (PE) 65020 Italy
de Burgos, 16 D 5ª planta
RATIOPHARM ESPAÑA, S.A. Avda. de Burgos, 16 D 5ª planta